Current:Home > StocksNew VA study finds Paxlovid may cut the risk of long COVID-DB Wealth Institute B2 Reviews & Ratings
New VA study finds Paxlovid may cut the risk of long COVID
lotradecoin trading account types View Date:2024-12-26 01:40:37
It's well-documented that Paxlovid — a 5-day course of antiviral pills from Pfizer — can reduce the risk of hospitalization in COVID-19 patients who are more likely to develop severe illness.
Now, researchers from the Veterans Health Administration find that taking the medication may also reduce the risks of later developing long COVID, according to a new study that was posted online this weekend and has not yet undergone peer review.
"We've already known for some time now that Paxlovid reduces the risk of acute problems," says Dr. Ziyad Al-Aly, chief of research and development at the VA Saint Louis Healthcare System, and co-author of the study, "Now we are adding the observation that Paxlovid also reduces the risk of long COVID."
The drug, which has been available in the U.S. for almost a year, is provided for free by the federal government at pharmacies across the country. It requires a prescription, and patients with COVID-19 must start it within five days of symptom onset.
Less virus, less long COVID?
In the study, long COVID was defined as developing one or more symptoms — including heart issues, blood disorders, fatigue and trouble breathing — one to three months after testing positive. By these metrics, patients that took Paxlovid were 26% less likely to develop long COVID.
To get to this finding, the researchers combed through electronic health records from more than 56,000 patients in the VA health system who tested positive for COVID-19 between March and June 2022, and had at least one risk factor for severe disease. They compared health outcomes of 9,000 patients that had taken Paxlovid early in their course of illness, with 47,000 patients that had not.
The benefits of taking Paxlovid didn't just apply to those who were unvaccinated. Patients who were vaccinated or boosted, or had repeat COVID-19 infections, had a similar reduction in the risk of developing long COVID, the study found.
The study is a preprint, meaning it was shared publicly before being reviewed and vetted by outside researchers. But experts who were not involved in the study tell NPR the findings make sense, given how Paxlovid works.
The antiviral drug stops the virus from replicating in cells. "We know that one of the key factors that predict long COVID is detectable virus in the bloodstream at the time of infection," Dr. Peter Chin-Hong, an infectious disease physician at the University of California, San Francisco, wrote in an email. "So it stands to reason that interventions that prevent the virus from making more copies of itself would therefore lead to a lower risk of long COVID."
Past studies have shown that Paxlovid reduces the risks of hospitalization and death from COVID-19. "Since the trigger of long COVID is acute infection with SARS-CoV-2, it makes intuitive sense that anything that lowers the severity of this infection would reduce the risk of long COVID, whether it's Paxlovid or other antiviral treatments," Dr. Paul Sax, an infectious disease physician at Brigham and Women's Hospital in Boston, wrote in an email.
A starting point
Still, experts view the study as only a starting point for exploring the potential uses of Paxlovid. The VA study was observational, based on data entered into patient health records – in Sax's view, "the imprecision of the [long COVID] diagnosis makes definitive conclusions from this study challenging, especially with a retrospective review."
But the value of the study is that it points researchers down promising pathways for more research, says Dr. Monica Gandhi, an infectious disease physician at UCSF. "It's hypothesis-generating," she says, "It's exciting and hopeful [to think] that if you reduce the viral load... down to undetectable [early in the illness], maybe you can prevent post-COVID symptoms" altogether – a theory she thinks researchers could pursue.
Both Sax and Gandhi say they would feel more confident in the results if they were replicated in additional studies, especially in experimental, randomized controlled trials that compare long COVID outcomes in patients who took either Paxlovid or a placebo. The VA study's findings are also limited by the fact that the participants were predominantly white men, raising the possibility that the benefits of Paxlovid could be different in other groups of patients.
Currently, Paxlovid is only authorized for use in patients who have risk factors – like being older or having underlying health conditions – that put them at high risk of developing severe disease. Al-Aly says the reduction in long COVID risk, raised in his study, suggests others might benefit from taking Paxlovid, too. But many patients who currently have long COVID were relatively young and healthy before they got COVID-19 and may not have qualified for Paxlovid when they tested positive, he says.
"Does Paxlovid use in a lower-risk population reduce the risk of acute problems and subsequently reduce the risk of long COVID?" Al-Aly wonders, "I think that's a question that we all need to solve over the next several months."
It's also an open question whether a higher dose or a longer treatment course could provide a greater benefit, Chin-Hong says.
Side effects that include nausea and an off-putting taste have given patients pause about using the product. Reports of COVID rebound in Paxlovid patients, where the illness flares up after a seeming respite, has made some prescribers ambivalent about the product. These are real considerations, Al-Aly says, but they should be weighed against the benefits of Paxlovid treatment, including reduced risks of hospitalization and death in the acute phase, and the potential for avoiding long COVID in the months after.
Gandhi says the study's findings may now factor into clinicians' decisions, even if the results are preliminary and have not yet been replicated.
"This study is pushing me to use [Paxlovid] in people who are over 65, vaccinated and boosted, because it's probably going to have other benefits beyond preventing hospitalization," she says.
veryGood! (5)
Related
- Detroit judge orders sleepy teenage girl on field trip to be handcuffed, threatens jail
- New Jersey denies bulkhead for shore town with wrecked sand dunes
- Mississippi House passes bill to legalize online sports betting
- Gigi Hadid and Bradley Cooper's Romance Is Far From the Shallow During NYC Outing
- Collin Gosselin claims he was discharged from Marines due to institutionalization by mom Kate
- Disney appeals dismissal of free speech lawsuit as DeSantis says company should ‘move on’
- Nikki Haley has called out prejudice but rejected systemic racism throughout her career
- U.S. travel advisory for Jamaica warns Americans to reconsider visits amid spate of murders
- Demi Lovato opens up about how 'daddy issues' led her to chase child stardom, success
- Mobsters stole a historical painting from a family; 54 years later the FBI brought it home
Ranking
- Justice Department defends Boeing plea deal against criticism by 737 Max crash victims’ families
- Warm weather forces park officials to suspend Isle Royale wolf count for first time in decades
- Camila Cabello Looks Unrecognizable With New Blonde Hair Transformation
- Maine man who fled to Mexico after hit-and-run killing sentenced to 48 years
- Jackson City Councilwoman Angelique Lee resigns after federal bribery charge
- A Tennessee teen has pleaded guilty in the slaying of a prominent United Methodist Church leader
- Heidi Klum’s NSFW Story Involving a Popcorn Box Will Make You Cringe
- Power outage at BP oil refinery in Indiana prompts evacuation, temporary shutdown
Recommendation
-
Police identify suspect in break-in of Trump campaign office in Virginia
-
Maine man who fled to Mexico after hit-and-run killing sentenced to 48 years
-
AP Week in Pictures: North America
-
Halle Bailey Reveals How She and Boyfriend DDG Picked Baby's Name
-
Conservative are pushing a ‘parental rights’ agenda in Florida school board races. But will it work?
-
Utah Legislature Takes Aim at Rights of Nature Movement
-
An armed man found dead at an amusement park researched mass shootings. His plan is still a mystery
-
Ex-CIA computer engineer gets 40 years in prison for giving spy agency hacking secrets to WikiLeaks
Tags
-
lotradecoin margin trading explained
lotradecoin token airdrop campaigns
lotradecoin tools
lotradecoin daily trading volume statistics
lotradecoin features
lotradecoin trading tutorial for beginners
lotradecoin trading fee structure
lotradecoin low trading fees advantage
lotradecoin mobile app features